project id: TCGA-BLCA; case submitter id: TCGA-UY-A78L; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.89; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.62; rna integrity number: 8.2; age at index: 62; days to birth: -22717; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; age at diagnosis: 22717; ajcc clinical t: T2; ajcc pathologic m: MX; ajcc pathologic n: N1; ajcc pathologic stage: Stage IV; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1127.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8130/3; primary diagnosis: Papillary transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to sample procurement: 0; initial weight: 150.0; portion submitter id: TCGA-UY-A78L-01A-12; percent lymphocyte infiltration: 4.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 5.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0;